Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma...read more
Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, raised $45 million by offering 3.8 million shares at $12, within the range of $11 to $13. The company offered 0.4 million more shares than...read more
Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, announced terms for its IPO on Monday. The Purchase, NY-based company plans to raise $40 million by offering 3.4 million shares at a price...read more
Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, filed on Monday with the SEC to raise up to $50 million in an initial public offering. Cognition Therapeutics is developing small molecule...read more
US IPO Weekly Recap: Healthcare and Canadian crosslistings lead an 8 IPO week
Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma...read more
Alzheimer's biotech Cognition Therapeutics prices upsized IPO at $12 midpoint
Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, raised $45 million by offering 3.8 million shares at $12, within the range of $11 to $13. The company offered 0.4 million more shares than...read more
Alzheimer's biotech Cognition Therapeutics sets terms for $40 million IPO
Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, announced terms for its IPO on Monday. The Purchase, NY-based company plans to raise $40 million by offering 3.4 million shares at a price...read more
Alzheimer's biotech Cognition Therapeutics files for a $50 million IPO
Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, filed on Monday with the SEC to raise up to $50 million in an initial public offering. Cognition Therapeutics is developing small molecule...read more